ARTICLE | Company News
Caris, Lustgarten deal
January 27, 2017 9:13 PM UTC
Caris and the foundation partnered to conduct a Phase II trial of melanoma drug Keytruda pembrolizumab in patients with microsatellite unstable tumors. Caris is responsible for trial enrollment, and L...
BCIQ Company Profiles